Article
Biochemistry & Molecular Biology
Junfeng Jiang, Yuanyuan Chen, Li Zhang, Qishu Jin, Liujun Wang, Sha Xu, Kexin Chen, Li Li, Tao Zeng, Xingfei Fan, Tingting Liu, Jiaxi Li, Jinjiang Wang, Chaofeng Han, Fu Gao, Yanyong Yang, Yue Wang
Summary: This study developed a new precise personalized strategy, named i-CRISPR, for cancer treatment by adding DNA damage repair inhibitors (i) and inducing cancer cell-specific DNA double strand breaks using CRISPR. The efficacy of this strategy was confirmed in multiple cancer models through in vitro and in vivo experiments, and the mechanism of cell death was revealed.
Article
Oncology
Haihua Huang, Zhentian Kai, Yuchen Wang, Xiaomiao Zhang, Jin Wang, Wei Zhang, Qian Xue, Hang Zhang, Hansong Jin, Peize Meng, Shuilong Zhang, Yueyue Yang, Honghua Yang, Wanning Liang, Guangbing Zha, Peng Luo, Yan Xu, Weiwei Shi, Zheng Ruan
Summary: In this study, we evaluated factors influencing the detection sensitivity of circulating tumor DNA (ctDNA) and found that histological subtypes and disease stages played significant roles in ctDNA detection rate. Additionally, we discovered that DNA extracted from bronchoalveolar lavage fluid had higher levels of ctDNA compared to plasma, suggesting its potential as a valuable sample source for tumor detection. Furthermore, tumor cellularity was shown to have a significant impact on the design of personalized ctDNA panels and the overall detection sensitivity.
Article
Biotechnology & Applied Microbiology
Songbai Zheng, Xiaodan Wang, Ying Fu, Beibei Li, Jianhua Xu, Haifang Wang, Zhen Huang, Hui Xu, Yurong Qiu, Yaozhou Shi, Kui Li
Summary: This study investigated genetic variations in Chinese NSCLC patients using next-generation sequencing, identifying common mutated genes and genes with copy number variation. GO and KEGG analyses revealed that these genes were mainly involved in tumor-related signaling pathways such as PI3K-Akt, FoxO, and Ras.
Article
Oncology
Laveniya Satgunaseelan, Sean Porazinski, Dario Strbenac, Aji Istadi, Cali Willet, Tracy Chew, Rosemarie Sadsad, Carsten E. Palme, Jenny H. Lee, Michael Boyer, Jean Y. H. Yang, Jonathan R. Clark, Marina Pajic, Ruta Gupta
Summary: A study identified a molecular signature of EGFR amplification and increased EGFR RNA abundance specific to young patients with oral squamous cell carcinoma (OSCC), suggesting EGFR amplification as a potential therapeutic target in this subset. Patient-derived cell lines with EGFR amplification showed sensitivity to the second-generation EGFR tyrosine kinase inhibitor afatinib. Testing for EGFR amplification could lead to more personalized treatment approaches and improved outcomes for younger OSCC patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Alexandra Carrier, Julien Prunier, William Poisson, Mallorie Trottier-Lavoie, Isabelle Gilbert, Maria Cavedon, Kisun Pokharel, Juha Kantanen, Marco Musiani, Steeve D. Cote, Vicky Albert, Joelle Taillon, Vincent Bourret, Arnaud Droit, Claude Robert
Summary: This study reports the development of a SNP-array for the endangered Rangifer tarandus using a multi-platform sequencing approach. A total of 63,336 SNPs were selected from a comprehensive catalog of SNPs detected in diverse populations. This SNP-array design allows for the assessment of genetic metrics related to population structure, inbreeding, and sex determination, and is of great importance for conservation planning.
Article
Oncology
E. Pleasance, A. Bohm, L. M. Williamson, J. M. T. Nelson, Y. Shen, M. Bonakdar, E. Titmuss, V Csizmok, K. Wee, S. Hosseinzadeh, C. J. Grisdale, C. Reisle, G. A. Taylor, E. Lewis, M. R. Jones, D. Bleile, S. Sadeghi, W. Zhang, A. Davies, B. Pellegrini, T. Wong, R. Bowlby, S. K. Chan, K. L. Mungall, E. Chuah, A. J. Mungall, R. A. Moore, Y. Zhao, B. Deol, A. Fisic, A. Fok, D. A. Regier, D. Weymann, D. F. Schaeffer, S. Young, S. Yip, K. Schrader, N. Levasseur, S. K. Taylor, X. Feng, A. Tinker, K. J. Savage, S. Chia, K. Gelmon, S. Sun, H. Lim, D. J. Renouf, S. J. M. Jones, M. A. Marra, J. Laskin
Summary: This study demonstrates the importance of comprehensive whole-genome and transcriptome sequencing and analysis in guiding personalized cancer therapy, resulting in positive clinical benefits for a significant proportion of patients.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Paolo Marchetti, Giuseppe Curigliano, Silvia Calabria, Carlo Piccinni, Andrea Botticelli, Nello Martini
Summary: The three current oncology models (histological, agnostic and mutational) have different regulatory procedures and implications in antineoplastic therapy access. Regulatory Agencies in histo-logical and agnostic models authorize target therapies and define their price, reimbursement, prescription and access based on clinical trials. The mutational model requires multidisciplinary skills but lacks standardized quality requirements for discussions. Real-world evidence from clinical practice is urgently needed. An indication-value-based sub iudice procedure of authorization could be a potential solution for access to therapy chosen by the mutational model.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Van-Anh Nguyen Hoang, Sao Trung Nguyen, Trieu Vu Nguyen, Thanh Huyen Pham, Phuoc Loc Doan, Ngoc Thanh Nguyen Thi, Minh Long Nguyen, Thi Cuc Dinh, Dinh Hoang Pham, Ngoc Mai Nguyen, Duy Sinh Nguyen, Du Quyen Nguyen, Y-Thanh Lu, Thanh Thuy Thi Do, Dinh Kiet Truong, Minh-Duy Phan, Hoai-Nghia Nguyen, Hoa Giang, Lan N. Tu
Summary: Breast cancer is the leading cause of cancer death in Vietnamese women. In this study, genomic DNA from tumor tissues of 134 early-stage breast cancer patients in Vietnam was sequenced to profile tumor-derived mutations. Personalized assays were used to detect circulating tumor DNA (ctDNA) in plasma samples collected before and after surgery. The mutational landscape in Vietnamese was similar to other Asian cohorts, with higher TP53 mutation frequency. The detection rate of ctDNA was associated with breast cancer subtypes and increased the risk of relapse. Post-operative detection of ctDNA preceded clinical diagnosis by 7-13 months in patients with recurrence.
MOLECULAR ONCOLOGY
(2023)
Article
Oncology
Michela Biancolella, Barbara Testa, Leila Baghernajad Salehi, Maria Rosaria D'Apice, Giuseppe Novelli
Summary: In recent years, rapid scientific innovation in individual genome evaluation has allowed for the identification of variants associated with the onset, treatment, and prognosis of various pathologies, including cancer. Despite the incomplete nature of the analysis and interpretation of genomic information, the identification of specific genomic profiles has allowed for the stratification of patient subgroups with better responses to drug therapies. Individual genome analysis has significantly changed the diagnostic and therapeutic approach to breast cancer in the last 15 years by identifying selective molecular lesions that drive tumor development, with each tumor having its own genomic signature and some features common to multiple subtypes.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Agronomy
Pasquale Tripodi, Rosa D'Alessandro, Giovanna Festa, Paola Taviani, Roberto Rea
Summary: This study confirmed the uniqueness and distinctness of the 'Peperone Cornetto di Pontecorvo' variety compared to similar pepper types through morpho-agronomic performance, chemical composition analysis, and genomic fingerprinting. The information obtained will be valuable for the recovery, enhancement, and protection of this local variety.
Article
Microbiology
Kayla Gisela Silva, Leonor Martins, Miguel Teixeira, Joel F. Pothier, Fernando Tavares
Summary: This study developed a DNA-marker-based method for the detection and genotyping of X. euroxanthea and proposed a workflow for the selection of species-specific detection markers. The method can track the presence of X. euroxanthea in microbial consortia and contribute to the control of phytopathogenic strains.
Article
Oncology
Kyoungmin Lee, Deokhoon Kim, Shinkyo Yoon, Dae Ho Lee, Sang-We Kim
Summary: After resistance to osimertinib, some tumors undergo transformation while others maintain T790M mutations. Novel mutations, including MET amplification, KRAS mutations, PIK3CA mutations, and RET fusion, are identified in patients with T790M loss.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Oncology
Kari Salokas, Giovanna Dashi, Markku Varjosalo
Summary: Cancer-associated gene fusions, known as oncofusions, are driving forces in oncogenesis and have revolutionized cancer research through advanced sequencing technologies. They manipulate cellular signaling pathways and show promise as targets for therapy and diagnostic markers. Further research is needed to understand their functional impact and harness their potential for precision cancer treatment.
Review
Oncology
Divya Chukkalore, Anisha Rajavel, Divya Asti, Meekoo Dhar
Summary: The incidence of endometrial cancer is increasing and treatment options for advanced disease are limited. Hormonal therapy has shown positive outcomes for Stage IV EC. Next generation sequencing has provided insights into the molecular mechanisms driving EC. In this case series, six Stage IV endometrial cancer patients being treated with hormonal therapy were studied. NGS data revealed common mutations, but none could predict the observed response to hormone therapy. It is suggested that NGS be frequently employed in endometrial cancer patients to identify targetable mutations.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Huu Thinh Nguyen, Trieu Vu Nguyen, Van-Anh Nguyen Hoang, Duc Huy Tran, Ngoc An Le Trinh, Minh Triet Le, Tuan-Anh Nguyen Tran, Thanh Huyen Pham, Thi Cuc Dinh, Tien Sy Nguyen, Ky Cuong Nguyen The, Hoa Mai, Minh Tuan Chu, Dinh Hoang Pham, Xuan Chi Nguyen, Thien My Ngo Ha, Duy Sinh Nguyen, Du Quyen Nguyen, Y-Thanh Lu, Thanh Thuy Do Thi, Dinh Kiet Truong, Quynh Tho Nguyen, Hoai-Nghia Nguyen, Hoa Giang, Lan N. Tu
Summary: This prospective multi-center study investigated the mutational landscape and actionable alterations in Vietnamese patients with colorectal cancer (CRC). The study identified the most common mutated genes and found that a significant percentage of patients had mutations predictive of resistance to certain drugs. The researchers also developed an assay to detect circulating tumor DNA (ctDNA) using personalized subsets of top ranked mutations. The assay showed promising results in residual cancer surveillance and actionable mutation profiling for targeted therapies in CRC patients.
FRONTIERS IN ONCOLOGY
(2022)
